Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report.

Q3 Medicine
Innovations in clinical neuroscience Pub Date : 2023-09-01 eCollection Date: 2023-07-01
David Wyndham Lawrence
{"title":"Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report.","authors":"David Wyndham Lawrence","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Migraine is a common neurovascular disorder with a pathophysiology related to the serotonin (5-hydroxytryptamine; 5-HT) system. Pharmacologic modulation of 5-HT receptors has demonstrated efficacy in the acute treatment of migraines. Psilocybin, a classic psychedelic with 5-HT receptor activity, has demonstrated therapeutic potential in the management of neuropsychiatric conditions. To date, no reports have investigated the effect of psilocybin administered acutely during a migraine episode.</p><p><strong>Case presentation: </strong>The case of a 33-year-old male patient with a history of migraines with aura, who had acute administration of oral psilocybin (in the form of the dried fruiting body of <i>Psilocybe cubensis</i> mushrooms) at migraine onset is presented. Headache intensity was rated hourly using the Numerical Rating Scale (NRS) and compared to three previous migraines. Profound reductions in headache intensity and emetic episodes were reported during the migraine treated acutely with oral psilocybin administration, compared to three previous migraines.</p><p><strong>Discussion: </strong>The severe, disabling, and treatment-resistant nature of migraines warrants continued surveillance for novel pharmacologic interventions. The established congruous pathophysiology of migraine and pharmacology of psilocybin, via the 5-HT receptor system, positions psilocybin as a potential therapeutic target.</p><p><strong>Conclusion: </strong>While this report highlights the potential role of psilocybin in the acute management of migraines, it is essential to note that it should not be considered a basis for guiding clinical practice at this point. Further research is necessary to establish the safety and efficacy of psilocybin as a treatment option for migraines.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"20 7-9","pages":"37-39"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561985/pdf/icns_20_7-9_37.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovations in clinical neuroscience","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Migraine is a common neurovascular disorder with a pathophysiology related to the serotonin (5-hydroxytryptamine; 5-HT) system. Pharmacologic modulation of 5-HT receptors has demonstrated efficacy in the acute treatment of migraines. Psilocybin, a classic psychedelic with 5-HT receptor activity, has demonstrated therapeutic potential in the management of neuropsychiatric conditions. To date, no reports have investigated the effect of psilocybin administered acutely during a migraine episode.

Case presentation: The case of a 33-year-old male patient with a history of migraines with aura, who had acute administration of oral psilocybin (in the form of the dried fruiting body of Psilocybe cubensis mushrooms) at migraine onset is presented. Headache intensity was rated hourly using the Numerical Rating Scale (NRS) and compared to three previous migraines. Profound reductions in headache intensity and emetic episodes were reported during the migraine treated acutely with oral psilocybin administration, compared to three previous migraines.

Discussion: The severe, disabling, and treatment-resistant nature of migraines warrants continued surveillance for novel pharmacologic interventions. The established congruous pathophysiology of migraine and pharmacology of psilocybin, via the 5-HT receptor system, positions psilocybin as a potential therapeutic target.

Conclusion: While this report highlights the potential role of psilocybin in the acute management of migraines, it is essential to note that it should not be considered a basis for guiding clinical practice at this point. Further research is necessary to establish the safety and efficacy of psilocybin as a treatment option for migraines.

西洛昔宾自行给药治疗偏头痛急性期1例报告。
背景:偏头痛是一种常见的神经血管疾病,其病理生理学与血清素(5-羟色胺;5-HT)系统有关。5-HT受体的药理学调节已证明在偏头痛的急性治疗中有效。Psilocybin是一种具有5-HT受体活性的经典迷幻药,已在神经精神疾病的治疗中显示出治疗潜力。到目前为止,还没有研究裸盖菇素在偏头痛发作期间急性给药的效果的报告。病例介绍:一名33岁男性患者,有先兆偏头痛病史,在偏头痛发作时急性口服裸盖菇素(以立方裸盖菇干燥子实体的形式)。每小时使用数字评定量表(NRS)对头痛强度进行评定,并与之前的三次偏头痛进行比较。据报道,与之前的三次偏头痛相比,口服裸盖菇素治疗急性偏头痛期间,头痛强度和呕吐发作显著减轻。讨论:偏头痛的严重性、致残性和耐药性需要继续监测新的药物干预措施。通过5-HT受体系统建立的偏头痛的病理生理学和裸盖菇素的药理学一致性,将裸盖菇蛋白定位为潜在的治疗靶点。结论:虽然本报告强调了裸盖菇素在偏头痛急性治疗中的潜在作用,但必须注意的是,目前不应将其视为指导临床实践的基础。需要进一步的研究来确定裸盖菇素作为偏头痛治疗选择的安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Innovations in clinical neuroscience
Innovations in clinical neuroscience Medicine-Psychiatry and Mental Health
CiteScore
2.10
自引率
0.00%
发文量
87
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信